You are here

Cancer Program

Berger AH, Brooks AN, Wu X, et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2017;32(6):884. doi:10.1016/j.ccell.2017.11.008.
Horn H, Lawrence MS, Chouinard CR, et al. NetSig: network-based discovery from cancer genomes. Nat Methods. 2017. doi:10.1038/nmeth.4514.
Subramanian A, Narayan R, Corsello SM, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171(6):1437-1452.e17. doi:10.1016/j.cell.2017.10.049.
Aguirre AJ, Hahn WC. Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harb Perspect Med. 2017. doi:10.1101/cshperspect.a031518.
Sharifnia T, Hong AL, Painter CA, Boehm JS. Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chem Biol. 2017;24(9):1075-1091. doi:10.1016/j.chembiol.2017.08.002.
Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a Cancer Dependency Map. Cell. 2017;170(3):564-576.e16. doi:10.1016/j.cell.2017.06.010.
Rheinbay E, Parasuraman P, Grimsby J, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55-60. doi:10.1038/nature22992.
Hsu JHao-Ru, Hubbell-Engler B, Adelmant G, et al. Prmt1-mediated translation regulation is a crucial vulnerability of cancer. Cancer Res. 2017. doi:10.1158/0008-5472.CAN-17-0216.
Ilic N, Birsoy K, Aguirre AJ, et al. PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A. 2017;114(17):E3434-E3443. doi:10.1073/pnas.1617922114.
Imielinski M, Guo G, Meyerson M. Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. Cell. 2017;168(3):460-472.e14. doi:10.1016/j.cell.2016.12.025.